Ultragenyx's high burn rate, costly R&D, and recent setbacks increase dilution risk, impacting future profitability. Learn ...

RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

The incumbent, Supervisor Eric Lucan, isn’t running for reelection. Instead, the Novato Democrat is vying to succeed ...

Carlsmed Inc. launched its IPO at a price of $14 to $16 per share for 6.7 million shares, which would raise just over $100.5 ...

This report also provides a detailed analysis of the current mucopolysaccharidosis marketed drugs and late-stage pipeline ...

NHS England has agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced its once-monthly PrEP ...

British engineering giant Rolls-Royce announced on Tuesday a $75 million investment to expand its manufacturing operations in ...